Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, which adds to its existing issues related to previous financial misconduct [1][2][3]. Group 1: Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan [1]. - The company had previously faced penalties for financial fraud, including a total of 1.029 billion yuan in inflated revenue and 669 million yuan in inflated profits over two years, leading to a fine of 10 million yuan and market bans for key executives [3]. Group 2: Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency issue [4]. - The company is under significant pressure from both the risk of delisting and a looming debt crisis, exacerbated by the recent regulatory penalties [4].

● 本报记者昝秀丽 证监会11月28日消息，近日，证监会对立方数科涉嫌定期报告财务数据存在虚假记载作出行政处罚及市 场禁入事先告知。 经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入 6.38亿元、成本6.28亿元。立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟 对立方数科处以1000万元罚款，对汪逸等10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强 制退市情形，深交所将依法启动退市程序。 同时，证监会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。 对于相关违法行为可能涉及的证券犯罪问题线索，证监会将坚持应移尽移的工作原则，依法依规移送公 安机关。 此案是首例上市公司领罚单，中介机构被同步立案的典型，体现了监管部门打击财务造假"追首 恶"与"打帮凶"并重的导向，标志着全方位、立体式的综合惩防体系进一步走向深入。 据悉，立方数科或是今年第14家因财务造假而涉嫌触及重大违法强制退市的公司，年内触及重大违法强 制退市的公司数量创历年新高。这一变化源于退市新规对财务造假退市标准的调整，也源于严监严管 下，监 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed administrative penalties on Lifan Shuke for falsifying financial data in periodic reports, marking a significant step in the crackdown on financial fraud in the market [1][2] Group 1: Company Actions and Penalties - Lifan Shuke inflated its revenue by 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities [1] - The Anhui Securities Regulatory Bureau plans to impose a fine of 10 million yuan on Lifan Shuke and a total of 30 million yuan on 10 responsible individuals, including Wang Yi [1] - The Shenzhen Stock Exchange will initiate delisting procedures for Lifan Shuke due to serious violations of securities laws and regulations [1] Group 2: Regulatory Environment - This case represents the first instance of a listed company receiving a penalty while its intermediary institution is also under investigation, highlighting the regulatory approach of targeting both the primary offenders and their accomplices [1] - Lifan Shuke is the 14th company this year to face mandatory delisting due to financial fraud, indicating a record high for such cases [2] - The increase in companies facing delisting is attributed to new regulations adjusting the standards for financial fraud and the CSRC's zero-tolerance stance towards such misconduct [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty against Lifan Shuke Co., Ltd. for financial fraud, which includes a total fine of 40 million yuan and the initiation of delisting procedures due to serious violations of securities laws [1][2]. Group 1: Financial Fraud Details - Lifan Shuke has inflated its revenue by 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities [2]. - The breakdown of inflated figures includes 280 million yuan in revenue and 277 million yuan in costs for 2021, 312 million yuan in revenue and 305 million yuan in costs for 2022, and 46 million yuan in revenue and 45 million yuan in costs for 2023 [2]. Group 2: Regulatory Actions - The CSRC has intensified its crackdown on financial fraud, with 14 companies facing potential delisting due to serious violations, marking a historical high [3]. - The CSRC has also decided to investigate the accounting firm involved in Lifan Shuke's case, marking a significant step in holding intermediary institutions accountable [4]. Group 3: Impact on Intermediary Institutions - Over 40 accounting firms have been penalized for negligence in financial fraud cases, with total fines exceeding 300 million yuan this year [4]. - The regulatory body has increased penalties against intermediary institutions to enhance accountability and deter collusion in fraudulent activities [5].

Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, amidst ongoing concerns about its previous financial misconduct and potential delisting [1][2][3][4]. Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan and a warning [1]. - This is not the first regulatory issue for R Puli 1; the company was previously penalized for financial fraud, which included inflating revenue by 1.029 billion yuan and profits by 669 million yuan over two years [3]. Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency situation [4]. - The company is under significant pressure due to the combination of delisting risks and a looming debt crisis, raising fears of potential defaults [4]. Company Background - R Puli 1 was established in 1992 and listed on the Growth Enterprise Market in 2017, previously recognized as one of China's top 100 innovative listed companies, with a diverse product line in various therapeutic areas [4].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued administrative penalties against Shenyang Chemical Co., Ltd. and several individuals for violations related to false financial disclosures from 2018 to 2021 [2][4][5]. Group 1: Violations and Findings - Shenyang Chemical's subsidiary, Shenyang Wax Chemical, manipulated financial data by adjusting production input quantities and delaying inventory recognition, leading to false reporting in annual reports [4][5]. - Specific financial discrepancies include: - 2018: Reduced operating costs by CNY 129.91 million, inflated profit by 80.44% [4]. - 2019: Reduced operating costs by CNY 204.50 million, inflated profit by 29.4% [4]. - 2020: Reduced operating costs by CNY 104.23 million, inflated profit by 19.14% [4]. - 2021: Inflated operating costs by CNY 147.76 million, reduced profit by 70.11% [4]. Group 2: Penalties Imposed - Shenyang Chemical was fined CNY 7 million and received a warning [9]. - Key individuals received the following penalties: - Sun Zesheng (Chairman and General Manager): fined CNY 3.5 million and banned from the securities market for 8 years [7][9]. - Li Zhong (Chief Accountant): fined CNY 3 million and banned for 4 years [8][9]. - Yang Lin (Director): fined CNY 1.2 million [9]. - Leng Zhaojia (Finance Head): fined CNY 1 million [9].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has proposed a fine of 10 million yuan against Lifan Technology (ST Lifan, 300344.SZ) for three consecutive years of financial fraud, with an additional 30 million yuan fine for 10 responsible individuals. The Shenzhen Stock Exchange will initiate delisting procedures due to serious violations [2][4]. Group 1: Financial Fraud Details - Lifan Technology inflated its revenue by a total of 638 million yuan and costs by 628 million yuan from 2021 to 2023, with specific annual inflations of 280 million yuan in revenue and 277 million yuan in costs for 2021, 312 million yuan and 305 million yuan for 2022, and 46 million yuan and 45 million yuan for 2023 [3]. - The company engaged in agency business, financing trade, and false trade to artificially inflate its financial statements [3]. Group 2: Regulatory Actions - The CSRC has decided to formally investigate the auditing firm Zhongxing Caiguanghua for its role in the fraudulent activities, as it issued standard unqualified audit reports for Lifan Technology from 2021 to 2023 [6][7]. - The proposed penalties against Lifan Technology and its executives are significantly higher than previous regulations, reflecting the new accounting law's stricter standards for financial fraud [6]. Group 3: Implications of Delisting - Lifan Technology's case is seen as a typical example of the enforcement of new regulations and a comprehensive accountability system, highlighting a zero-tolerance approach to financial fraud [6][7]. - The initiation of delisting procedures by the Shenzhen Stock Exchange indicates a serious consequence for companies involved in major violations, aiming to reduce the occupancy of market resources by substandard firms [6].

中国证监会11月28日宣布，对上市公司立方数科股份有限公司（立方数科）涉嫌定期报告财务数据存在 虚假记载作出行政处罚及市场禁入事先告知。 证监会表示，决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。 对于相关违法行为可能涉及的证券犯罪问题线索，证监会将坚持应移尽移的工作原则，依法依规移送公 安机关。（记者刘慧、刘羽佳） 证监会信息显示，经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方 式，累计虚增收入6.38亿元、成本6.28亿元。其中，2021年收入、成本分别虚增2.80亿元、2.77亿元， 2022年收入、成本分别虚增3.12亿元、3.05亿元，2023年收入、成本分别虚增0.46亿元、0.45亿元。立方 数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟对立方数科处以1000万元罚款， 对汪逸等10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强制退市情形，深交所将依法启动 退市程序。 【纠错】 【责任编辑:谷玥】 ...

11月28日，*ST元成(603388.SH)公告称，公司于11月28日收到上交所出具的《关于元成环境股份有限公司股票终止上市的决定》，上交所决定终止公司股 票上市。公司终止上市暨摘牌日为2025年12月5日。 公司股票终止上市后，将转入全国中小企业股份转让系统依托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块挂牌转让。 *ST元成将于12月5日终止上市。 2025年10月10日，证监会对*ST元成涉嫌定期报告等财务数据存在虚假记载作出行政处罚并事先告知，*ST元成涉嫌触及重大违法强制退市情形，上交所 将依法启动退市程序。 证监会官网显示，*ST元成连续三年虚增收入和利润，违反证券法律法规。经查明，*ST元成主要通过以下手段造假： 一是虚增越龙山项目成本与产值，导致2020年至2022年年报中的营业收入和利润总额严重失实。 其中，*ST元成累计虚增营业成本约1.58亿元、营收2.09亿元、利润总额达5046.02万元。其中，2020年年报虚增利润总额3848.04万元，占当期披露金额的 36.60%；2021年年报虚增利润总额1109.39万元，占当期披露金额的19.32%；2022年年报虚 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ *ST元成（维权）将于12月5日终止上市。 11月28日，*ST元成（603388.SH）公告称，公司于11月28日收到上交所出具的《关于元成环境股份有 限公司股票终止上市的决定》，上交所决定终止公司股票上市。公司终止上市暨摘牌日为2025年12月5 日。 公司股票终止上市后，将转入全国中小企业股份转让系统依托原证券公司代办股份转让系统设立并代为 管理的两网公司及退市公司板块挂牌转让。 2025年10月10日，证监会对*ST元成涉嫌定期报告等财务数据存在虚假记载作出行政处罚并事先告知， *ST元成涉嫌触及重大违法强制退市情形，上交所将依法启动退市程序。 证监会官网显示，*ST元成连续三年虚增收入和利润，违反证券法律法规。经查明，*ST元成主要通过 以下手段造假： 一是虚增越龙山项目成本与产值，导致2020年至2022年年报中的营业收入和利润总额严重失实。 其中，*ST元成累计虚增营业成本约1.58亿元、营收2.09亿元、利润总额达5046.02万元。其中，2020年 年报虚增利润总额3848.04万元，占当期披露金额的36.60%；20 ...